Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. The company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company's main capabilities include clinical development, vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. The company is conducting a clinical trial for its gene therapy candidate ADVM-022, AAV.7m8-aflibercept, for the treatment of wet age-related macular degeneration.

Air Transport Services Group is a holding company. Through its subsidiaries, the company owns and leases aircraft to external customers and its airline subsidiaries. The company's services include: Aircraft Leasing, which owns and leases aircraft through its subsidiary Cargo Aircraft Management, Inc.; Airline Operations, which provides various combinations of aircraft, crews, maintenance and insurance to provide customized transportation capacity through its subsidiaries, ABX Air, Inc., Air Transport International, Inc. and Omni Air International, LLC; and Support Services, which provides air transportation related services including aircraft maintenance and modification, ground handling and crew training.

Anixa Biosciences is a biotechnology company focused on using the body's immune system to diagnose, treat and prevent cancer. The company's subsidiary, Anixa Diagnostics Corporation, develops Cchek?, a platform for non-invasive blood tests for the early detection of cancer. The company's subsidiary, Certainty Therapeutics, Inc., develops immuno-therapy drugs against cancer. The company has focused on the development of a treatment for ovarian cancer. The company is also engaged in limited patent licensing activities in the area of encrypted audio/video conference calling.

Atlanticus Holdings is a holding company. Through its subsidiaries, the company provides various credit and related financial services and products. The company has two segments: Credit and Other Investments, whereby the company supports lenders who originate consumer loan products that include retail credit and credit cards marketed through various channels, including retail point-of-sale, direct mail solicitation, and partnerships with third parties; and Auto Finance, which purchases and/or services loans secured by automobiles from or for, and also provides floor plan financing for, a pre-qualified network of automotive dealers and automotive finance companies in the buy-here, pay-here, used car business.

CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products. The company's primary product and candidates in hematology/oncology include: EVOMELA (Melphalan for Injection), an intravenous formulation of melphalan commercialized in the multiple myeloma treatment setting in the United States; CNCT19, which targets CD19, a B-cell surface protein expressed during all phases of B-cell development and a validated target for B-cell driven hematological malignancies; CID-103, an investigational anti-CD38 monoclonal antibody being developed for the treatment of patients with multiple myeloma.

Century Bancorp is a bank holding company. Through its subsidiary, Century Bank and Trust Company, the company provides services to commercial enterprises, state and local governments and agencies, non-profit organizations and individuals. The company also provides securities brokerage services through a program called Investment Services at Century Bank, which is supported by LPL Financial, a third party securities brokerage business. The company grants single-family and multi-family residential loans, commercial and commercial real estate loans, municipal loans, and a variety of consumer loans. In addition, the company provides savings accounts, NOW accounts, demand deposits, time deposits and money market accounts.

Crinetics Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. CRN00808, the company's primary product candidate, establishes oral selective nonpeptide somatostatin receptor type 2 (sst2) biased agonists designed for the treatment of acromegaly. CRN01941, an oral nonpeptide sst2 biased agonist, is designed for the treatment of neuroendocrine tumors that originate from neuroendocrine cells commonly found in the gut, lung or pancreas. The company is developing a class of oral selective nonpeptide somatostatin type 5 receptor agonists designed to treat congenital hyperinsulinism.

Designer Brands is a footwear and accessories designer, producer and retailer. The company has three segments: U.S. Retail, which includes stores operated in the U.S. under the DSW Designer Shoe Warehouse banner and its related e-commerce site; Canada Retail, which includes stores operated in Canada under The Shoe Company, Shoe Warehouse, and DSW Designer Shoe Warehouse banners and related e-commerce sites; and Brand Portfolio, which includes sales from wholesale, serving retailers as the design and buying agent for products under private labels, and direct-to-consumer e-commerce sites. The company separates its merchandise into three categories: women's footwear; men's footwear; and accessories and other.

Stellar Biotechnologies is a biotechnology company engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH) protein. KLH can be used as an active pharmaceutical ingredient and combined with a disease-targeting agent to create immunotherapies for the treatment of a variety of diseases. The protein is being utilized in active immunotherapies in clinical development for Alzheimer's disease, metastatic breast cancer, Crohn's disease, systemic lupus erythematous, ovarian cancer and various other cancers and diseases.

Gold Resource produces metal concentrates that contain gold, silver, copper, lead and zinc, and dore containing gold and silver from the Aguila and Alta Gracia Projects in the southern state of Oaxaca, Mexico. The Aguila Project includes the Arista underground mine and processing facility. The Alta Gracia project includes the Mirador underground mine. The company also performs exploration and evaluation work of precious metal properties in Nevada. The company's operations in Oaxaca, Mexico are conducted through its subsidiary, Don David Gold Mexico S.A.de C.V. The company's Nevada exploration, development and construction work is performed through two subsidiaries, GRC Nevada Inc. and Walker Lane Minerals Corp.

Green Brick Partners is a homebuilding and land development company. The company acquires and develops land, provides land and construction financing to its controlled builders and participates in the profits of its builders. The company is engaged in homebuilding process, including land acquisition and development, entitlements, design, construction, title and mortgage services, marketing and sales and the creation of brand images at its residential neighborhoods and communities. The company sells finished lots to its controlled builders or option lots from third-party developers for its controlled builders' homebuilding operations and provides them with construction financing and strategic planning.

Home Federal Bancorp is a savings and loan holding company. Through its subsidiary, Home Federal Bank, the company provides financial services to individuals, corporate entities, and other organizations through the origination of loans and the acceptance of deposits in the form of passbook savings, certificates of deposit, and demand deposit accounts. The company's loan portfolio consists of: one-to-four family residential real estate loans; commercial real estate secured loans; multi-family residential loans; commercial business loans; land loans; construction loans; home equity and second mortgage loans; equity lines of credit; and consumer non-real estate loans.

Kingsway Financial Services is a holding company. Through its subsidiaries, Co. operates as a merchant bank engaged in the property and casualty insurance business. Co. operates three segments: Insurance Underwriting, which markets automobile insurance products that provide coverage in three main areas: liability, accident benefits and physical damage; Insurance Services, which includes IWS Acquisition Corporation, a licensed motor vehicle service agreement company, and Trinity Warranty Solutions LLC, a provider of warranty products and maintenance support; and Leased Real Estate, which includes Co.'s subsidiary, CMC Industries, Inc., that owns a parcel of real property located in Texas.

Molecular Templates is a clinical-stage company focused on the discovery and development of biologic therapeutic for cancer and other serious diseases. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies (ETBs). The company is developing ETBs for various targets, including CD20, CD38, HER2, PD-L1, CTLA-4, SLAMF-7, and CD45. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of various myeloma. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.

Novan is a clinical development-stage biotechnology company focused on utilizing nitric oxide's naturally occurring anti-viral, anti-bacterial, anti-fungal and immunomodulatory mechanisms of action to treat a range of diseases with unmet needs. The company's product candidates are: SB204, a once-daily, topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails; and SB414, a topical cream-based product candidate for the treatment of inflammatory skin diseases.

Overseas Shipholding Group is a holding company. Through its subsidiaries, the company owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products in the U.S. Flag trades. The company has one reportable business segment. The company's U.S. Flag Fleet consists of various owned and chartered-in Jones Act Handysize Product Carriers and Articulated Tug Barges and non-Jones Act U.S. Flag Handysize Product Carriers that participate in the U.S. Maritime Security Program. Under the Jones Act, shipping between U.S. ports, including the movement of Alaskan crude oil to U.S. ports, is reserved for U.S. Flag vessels.

Republic Services is a provider of non-hazardous solid waste collection, transfer, disposal, recycling, and environmental services in the United States. The company operates through collection operations, transfer stations, active landfills, recycling processing centers, treatment, recovery and disposal facilities, salt water disposal wells, and deep injection wells. In addition, the company is engaged in landfill gas-to-energy and renewable energy projects and had post-closure responsibility for closed landfills. The company's operations primarily consist of providing collection, transfer and disposal of non-hazardous solid waste, recovering and recycling of certain materials, and environmental services.

REV Group is a holding company. Through its subsidiaries, the company is a designer, manufacturer and distributor of specialty vehicles and related aftermarket parts and services. The company provides customized vehicle solutions for applications including: essential needs (ambulances, fire apparatus, school buses and municipal transit buses), industrial and commercial (terminal trucks, cut-away buses and sweepers) and consumer leisure (recreational vehicles (RVs), and coaches). The company's segments are: Fire and Emergency, which sells fire apparatus equipment and ambulances; Commercial, which produces buses, terminal trucks and sweepers; and Recreation, which provides motorized and towable RV models.

Rocket Pharmaceuticals is a clinical-stage, multi-platform biotechnology company focused on the development of gene therapies for rare and devastating pediatric diseases. The company has the following inical-stage ex vivo lentiviral vector programs enrolling patients in the U.S. and European Union for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

Science Applications International provides technical, engineering and enterprise information technology (IT) services. The company provides engineering, systems integration and information technology offerings for government projects and provides a range of services with an emphasis on differentiated technology services. The company's offerings include: engineering; technology and equipment platform integration; maintenance of ground and maritime systems; logistics; training and simulation; operation and program support services; and end-to-end services spanning the design, development, integration, deployment, management and operations, sustainment and security of its customers' entire IT infrastructure.

Solid Biosciences is engaged in the treatment of Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys, with symptoms that manifest between three and five years of age. The company's primary gene transfer candidate, SGT-001 is designed to address the underlying genetic cause of DMD by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. The company's portfolio also includes an initial disease modifying candidate, Anti-LTBP4, a monoclonal antibody designed to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein.

Veritiv is a business-to-business distributor of packaging, facility solutions, print and publishing products and services. Co has the following reportable segments: Packaging, which provides standard as well as custom packaging solutions; Facility Solutions, which sources and sells cleaning, break-room and other supplies such as towels, tissues, wipers and dispensers, can liners, commercial cleaning chemicals, soaps and sanitizers; Print, which sells and distributes commercial printing, writing, copying, digital, specialty products, graphics consumables and graphics equipment; and Publishing and Print Management, which sells and distributes coated and uncoated commercial printing papers.

Verrica Pharmaceuticals is a dermatology therapeutics company focused on the development and commercialization of treatments for people living with skin diseases. The company's primary product candidate, VP-102, is a proprietary drug-device combination of its topical solution of cantharidin, a naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is initially developing VP-102 for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts. In addition, the company is also developing VP-102 for the treatment of external genital warts.